Invex Therapeutics Ltd (ASX:IXC)

Market Cap	9.77M
Revenue (ttm)	229.08K -81.1%
Net Income	-476.87K
EPS	-0.01
Shares Out	75.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,243
Average Volume	78,179
Open	0.1300
Previous Close	0.1200
Day's Range	0.1200 - 0.1300
52-Week Range	0.0590 - 0.1800
Beta	0.20
RSI	55.40
Earnings Date	Feb 5, 2026

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, A...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IXC

Financial Performance

In fiscal year 2025, Invex Therapeutics's revenue was 229,084, a decrease of -81.10% compared to the previous year's 1.21 million. Losses were -476,868, -70.95% less than in 2024.